"Merck KGaA said that its immunotherapy Bavencio jointly developed with Pfizer delayed the progression of kidney cancer when used in combination with Pfizers Inlyta drug in a latestage study.  The drug combination led to longer progressionfree survival in patients with advanced renal cell carcinoma RCC when compared with a control group on older Pfizer drug Sutent the German drugmaker said in a statement on Tuesday.  The trial will continue to show whether Bavencio plus Inlyta also prolongs patients lives.  While the company said the benefit was statistically significant they did not specify the duration of progressionfree survival. A detailed analysis would be submitted for presentation at a medical congress it added.  Reporting by Ludwig Burger Editing by Maria Sheahan Our StandardsThe Thomson Reuters Trust Principles httpthomsonreuters.comenaboutustrustprinciples.html"